Veracyte Inc. Common Stock (VCYT)

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diag…

Sector

Health Care

Industry

Medical Specialities

Employees

755

Website

www.veracyte.com/

Fundamentals

1-day range

$43.32$45.55

Market cap

$3.71B

P/E (trailing)

29.24

P/E (forward)

22.25

EPS (trailing)

$1.40

Dividend yield

—

Beta

1.98

Avg. volume

1.36M

Forecasts

11 analyst ratings

Veracyte Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VCYT

  Veracyte Inc. Common Stock

  $43.36

  ▼ 4.19%
  Market cap $3.71BP/E 29.24
  $28.25$60.91
• CON

  Concentra Group Holdings Parent Inc. Common Stock

  $34.24

  ▼ 1.33%
  Market cap $3.91BP/E 22.86
  $18.55$35.52
• BLLN

  BillionToOne Inc. Class A Common Stock

  $93.27

  ▼ 1.98%
  Market cap $4.22BP/E 117.67
  $61.96$150.44
• CELC

  Celcuity Inc. Common Stock

  $88.46

  ▼ 5.13%
  Market cap $4.55BP/E —
  $44.42$151.02
• GRAL

  GRAIL Inc. Common Stock

  $79.94

  ▼ 3.10%
  Market cap $2.72BP/E —
  $30.82$118.84
• CLOV

  Clover Health Investments Corp. Class A Common Stock

  $4.22

  ▼ 0.24%
  Market cap $2.45BP/E —
• CDNA

  CareDx Inc. Common Stock

  $49.73

  ▼ 5.02%
  Market cap $2.32BP/E 22.08
  $12.37$53.67

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Top 3 Health Care Stocks That Could Blast Off This Month
  benzinga · 8/19/2026
• Top 3 Health Care Stocks That Could Blast Off This Month
  Benzinga · 8/19/2026
• Veracyte: Diagnostics With Favorable Economics
  SeekingAlpha · 8/10/2026
• Veracyte: Core Growth Funds Prosigna And TrueMRD
  SeekingAlpha · 8/9/2026
• Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential
  ChartMill · 8/5/2026
• Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
  Benzinga · 8/4/2026
• Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55
  Benzinga · 8/4/2026
• Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
  Benzinga · 8/4/2026
• Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50
  Benzinga · 8/3/2026

• Karin Eastham · June 18, 2026 · Sale

  529 @ $53.55
• Karin Eastham · June 18, 2026 · Sale

  3.2K @ $52.78
• Thomas F. Miller · June 11, 2026 · Grant

  5.3K
• Eliav Barr · June 11, 2026 · Grant

  5.3K
• Muna Bhanji · June 11, 2026 · Grant

  5.3K
• Jens Holstein · June 11, 2026 · Grant

  5.3K
• David Brent Shafer · June 11, 2026 · Grant

  5.3K
• Robert S. Epstein · June 11, 2026 · Grant

  5.3K
• Karin Eastham · June 11, 2026 · Grant

  5.3K
• JONES EVAN/ FA · June 11, 2026 · Grant

  5.3K
• John Leite · June 4, 2026 · Sale

  14.0K @ $50.07
• Annie McGuire · June 4, 2026 · Sale

  1.8K @ $50.12
• Annie McGuire · June 4, 2026 · Sale

  1.4K @ $49.31
• Rebecca Chambers · June 4, 2026 · Sale

  2.0K @ $50.09
• Rebecca Chambers · June 4, 2026 · Sale

  1.6K @ $49.28

Institutional Ownership

March 31, 2026

Total shares held

82.63M

Total value held

$2.59B

Institutional holders

326